Nogo-A Antibody - new trial has started

The purpose of the NISCI trial, is to test if an antibody therapy (anti-Nogo-A) can improve movement and quality of life of tetraplegic patients. A previous trial showed that this treatment is safe and well accepted. This current trials has been approved by the National Ethics Committee and Ministry of Health for all participating trial sites in Switzerland. The NISCI trial is a multicenter, multinational, placebo controlled phase-II study which is being conducted in several European countries such as Switzerland, Germany, Italy, Spain and the Czech Republic.

For further information:

Email: nisci@balgrist.ch

https://nisci-2020.eu


Brain Research Institute, University of Zurich
ClinicalTrials.gov